ABA Will Back Myriad's Gene Patents In Supreme Court

Law360, Dallas (February 11, 2013, 4:58 PM ET) -- The American Bar Association voted Monday to back Myriad Genetics Inc.’s bid to retain patents for isolated breast cancer genes and to oppose a Federal Circuit ruling that lowered the bar for claiming joint patent infringement in amicus briefs with the U.S. Supreme Court.

The ABA’s House of Delegates resolved at its Midyear Meeting in Dallas to file an amicus brief with the high court in Association for Molecular Pathology v. Myriad Genetics Inc. arguing patents should not be excluded as naturally occurring under Section 101...
To view the full article, register now.